Key Highlights
- Yun Zhong, PhD, appointed as Senior Vice President, Equity Research at Wedbush Securities, specializing in biotechnology.
- Zhong initiates coverage on eight biotech stocks, including Ascendis Pharma (ASND), BioMarin Pharmaceuticals (BMRN), and Voyager Therapeutics (VYGR).
- Zhong’s expertise spans orphan diseases, genetic medicine, hematology, and metabolic disorders.
- Formerly at Jefferies, Zhong also held senior roles at Cowen and Company, SunTrust Robinson Humphrey, and more.
- Zhong earned his PhD in neuroscience and molecular biology from Rockefeller University.
Source: Business Wire
Notable Quotes
- “Joining Wedbush is a fantastic opportunity to be part of a firm with a strong reputation and a well-established presence in biotech. The collaborative and collegial atmosphere here is exceptional, and I am eager to contribute to the research being conducted by this talented team.” — Yun Zhong, PhD, Senior Vice President, Equity Research at Wedbush Securities
- “Yun’s technical expertise and deep understanding of the field will greatly enhance our Healthcare Research team. His insights will be invaluable as we continue to provide our clients with top-tier analysis and support in this dynamic sector.” — Kevin Merritt, Director of Research at Wedbush Securities
SoHC's Take
Yun Zhong’s appointment as SVP of Equity Research marks a significant step forward for Wedbush Securities’ Healthcare Equity Research team. His broad expertise in biotechnology, spanning critical areas such as orphan diseases and genetic medicine, will provide clients with unparalleled insights. By initiating coverage on eight diverse biotech companies, Zhong signals a proactive and comprehensive approach to equity research. This strategic addition strengthens Wedbush’s leadership in the financial services and biotech investment space.
